Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682476 | 0.94 | ALK (0.39) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL6540531 | 0.88 | CA1 (0.41) | CA1CA2CA9STS | |
| SCHEMBL6541242 | 0.88 | CA1 (0.40) | CA1CA2CA7CA9NLRP3 | |
| SCHEMBL6541141 | 0.87 | NLRP3 (0.49) | NLRP3ALDH1A1 | |
| SCHEMBL6540091 | 0.87 | TSHR (0.47) | CA1CA2CA7CA9NLRP3 | |
| SCHEMBL6541275 | 0.87 | PTPN1 (0.47) | ALDH1A1CYP1A2CYP3A4GAACYP2D6 | |
| SCHEMBL6540929 | 0.87 | TSHR (0.47) | CA1CA2CA7CA9NLRP3 | |
| SCHEMBL6805239 | 0.83 | TSHR (0.38) | CA1CA2CA7CA9NLRP3 | |
| SCHEMBL6679678 | 0.83 | POLB (0.43) | CA1CA2CA7GAA | |
| SCHEMBL6540276 | 0.82 | CA1 (0.55) | CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CA1 4181/4885CA2 2242/4885CA7 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.